Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study
Table 1
Patient characteristics.
Parameter
Safety analysis set
= 808
Age
Mean ± SD [years]
34.7 ± 12.3
Median [years]
33.0
Range [years]
18–82
Sex
Male [ (%)]
364 (45.0)
Female [ (%)]
444 (55.0)
Symptoms
Allergic rhinitis [ (%)]
804 (99.5)
Severity in the grass pollen season 2008 [ (%)]
Mild
41 (5.1)
Moderate
323 (40.0)
Severe
433 (53.6)
Allergic conjunctivitis [ (%)]
625 (77.4)
Severity in the grass pollen season 2008 [ (%)]
Mild
167 (20.7)
Moderate
301 (37.3)
Severe
232 (28.7)
Allergic asthma [ (%)]
189 (23.4)
Allergy history
Mean ± SD duration since first occurrence [years]
Allergic rhinitis
10.2 ± 9.0
Allergic conjunctivitis
10.7 ± 9.2
Allergic asthma
9.2 ± 9.7
History of immunotherapy [ (%)]
No (first time immunotherapy)
634 (78.5)
Yes, completed
146 (18.1)
Yes, switch from an ongoing immunotherapy
28 (3.5)
Concomitant allergies
Yes [ (%)]
580 (71.8)
Concomitant allergies to [ (%)]
Birch pollen
394 (48.8)
Other tree pollens
332 (41.1)
Weed pollens
233 (28.8)
House dust mites
219 (27.1)
Animal dander
184 (22.8)
Moulds
71 (8.8)
Symptomatic medication
Symptomatic medication intake during the grass pollen season 2008 [ (%)]
